We encourage shareholders to exercise their rights by submitting proxies or votes by corresponde Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd ...

Better-than-expected price data can’t quite blunt worries about consumers pulling back, as companies keep scrambling to ...

The index absorbs the stocks representing the largest 98% of the collective market—with buffers around the edge to reduce unnecessary trading ... Giants like SAP, Novo Nordisk, and Nestle ...

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies.

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Its industry sports an average Forward P/E of 14.67, so one might conclude that Novo Nordisk is trading at a premium comparatively. It's also important to note that NVO currently trades at a PEG ...

Bearish flow noted in Novo Nordisk (NVO) with 7,917 puts trading, or 1.2x expected. Most active are 3/14 weekly 76 puts and Sep-25 110 puts, ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.